首页> Annals of oncology : official journal of the European Society for Medical Oncology> A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

导出 OA

翻译打印收藏纠错

第一作者： L A,Dunn

第一单位： Section of Head and Neck Oncology, Division of Solid Tumor, Department of Medicine;. Electronic address: dunnl1@mskcc.org.

作者： L A,Dunn ^[1] ; M G,Fury ^[2] ; H,Xiao ^[2] ; S S,Baxi ^[2] ; E J,Sherman ^[2] ; S,Korte ^[2] ; C,Pfister ^[2] ; S,Haque ^[3] ; N,Katabi ^[4] ; A L,Ho ^[2] ; D G,Pfister ^[2]

作者单位： Section of Head and Neck Oncology, Division of Solid Tumor, Department of Medicine;. Electronic address: dunnl1@mskcc.org. ^[1] Section of Head and Neck Oncology, Division of Solid Tumor, Department of Medicine. ^[2] Department of Radiology. ^[3] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. ^[4]

关键词 head and neck cancer mTOR inhibition squamous cell carcinoma temsirolimus